WilmerHale Advises Nabriva Therapeutics in Recent Acquisition and Public Offering

WilmerHale Advises Nabriva Therapeutics in Recent Acquisition and Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

On July 26, 2018, Nabriva Therapeutics plc (NASDAQ:NBRVF), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, announced the pricing of its underwritten public offering of 18,181,818 ordinary shares at a public offering price of $2.75 per share. In addition, Nabriva Therapeutics granted the underwriters an option for a period of 30 days to purchase up to an additional 2,727,272 ordinary shares at the public offering price, less the underwriting discounts and commissions.

Two days prior, Nabriva Therapeutics announced that it acquired Zavante Therapeutics, a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, for upfront consideration of approximately 8.2 million of Nabriva Therapeutics' ordinary shares (which includes an indemnity holdback) to Zavante’s former stockholders upon completion of the acquisition. In addition, Zavante’s former stockholders are eligible to receive up to $97.5 million upon the achievement of specified regulatory and commercial milestones, which subject to approval by Nabriva Therapeutics' shareholders and specified limitations, may be settled in Nabriva Therapeutics' ordinary shares.

WilmerHale acted as legal advisor to Nabriva Therapeutics in these transactions, with Brian Johnson leading a team that included Joe Conahan, Jeffries Oliver-Li, Mark Nylen and Ryan Crane (M&A); Kimberly Wethly and Ciara Baker (executive compensation); Amy Null (benefits); Richard Andersen, Julie Hogan Rodgers and Meghan Walsh (tax); Colleen Superko (intellectual property); Bruce Manheim (FDA); Belinda Juran (technology transactions & licensing); Heidi Treiber (Nasdaq matters); and Sarah Sellers, Alicia Lee, Libby Ragan and Morgan Monroe (public offering and general corporate).

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel